SGIOY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 01:29):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan...

Stats
आज की मात्रा	213 331
औसत मात्रा	129 788
बाजार मूल्य	11.18B
EPS	$122.20 ( Q4 \| 2024-03-31 )
अगली कमाई की तारीख	( $0 ) 2024-07-29
Last Dividend	$0.121 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	11.16 (Sector) 0 (Industry) 0
ATR14	$0.0110 (0.11%)

ACRDF 0.00%

ACRHF 0.00%

APNHY 0.00%

AVTBF 0.63%

AYRWF -14.89%

BBBT 0.00%

BLMS -9.09%

CBDHF 0.00%

CBGL 0.00%

CCHWF -21.71%

CENBF 0.00%

CHALF -99.00%

CNTTQ 0.00%

CRLBF -11.73%

CRYM -1.48%

DVAXW 9 900.00%

DVLP 0.00%

EAPH 12.03%

EDXC 55.17%

EMHTF 0.00%

ESALF -2.11%

ESALY 12.50%

ETST 11.90%

GDNSF -3.00%

GLASF 0.00%

GNHAY -15.36%

GRAMF 9 900.00%

HCANF 0.00%

HKMPY 0.00%

HLUYY 0.00%

HYEX -1.11%

HYPMY 0.00%

IPSEY 1.06%

ITHUF -18.67%

JUSHF 20.00%

KGKG 0.00%

LOWLF 0.00%

LVRLF 0.00%

MILC -1.14%

MKKGY -66.67%

NLBS 0.00%

NPHC 0.00%

NPPNY 0.00%

NUNZ 7.50%

ORXOY 2.13%

PLNHF 0.00%

PZOO -26.83%

RLBD 1.82%

RWBYF 0.21%

SGIOY 0.00%

TAIPY -12.10%

TCNNF 0.00%

TEVJF 0.00%

TLGTQ -11.79%

TRSSF -7.41%

UNRV -2.59%

VEXTF -13.10%

VLNCD 0.00%

VRNOF 0.00%

सहसंबंध (AI algo v.1.1b): Undervalued: 0.03% $9.71 paired level. (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

मात्रा सहसंबंध

लंबा: 0.14 (neutral)

छोटा: -0.08 (neutral)

Signal:(54.573) Neutral

Shionogi & Co., Ltd. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Shionogi & Co., Ltd. सहसंबंध - मुद्रा/वस्त्र

-0.54
( weak negative )

-0.47
( neutral )

0.00
( neutral )

0.38
( neutral )

0.00
( neutral )

0.44
( neutral )

Shionogi & Co., Ltd. वित्तीय

Annual	2024
राजस्व:	$435.08B
सकल लाभ:	$369.09B (84.83 %)
EPS:	$558.51

FY	2024
राजस्व:	$435.08B
सकल लाभ:	$369.09B (84.83 %)
EPS:	$558.51

FY	2023
राजस्व:	$426.68B
सकल लाभ:	$356.58B (83.57 %)
EPS:	$621.31

FY	2022
राजस्व:	$335.14B
सकल लाभ:	$272.41B (81.28 %)
EPS:	$378.75

Financial Reports:

No articles found.

Shionogi & Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Shionogi & Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.85 - Stable (16.96%)

Information

First Dividend	$0.124	2021-03-29
Last Dividend	$0.121	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.245	--
Avg. Dividend % Per Year	0.00%	--
Score	3.71	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.85
Div. Directional Score	8.95	--

Next Divdend (Est)
(2024-12-19)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.71

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
28 Sep 2021	$0.121	30 Nov -0001	30 Nov -0001	30 Nov -0001
29 Mar 2021	$0.124	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
UEPCP	Ex Dividend Knight	2023-07-20	Quarterly	0.00%
FBPI	Ex Dividend Knight	2023-08-30	Quarterly	0.00%
PUBGY	Ex Dividend Knight	2023-06-30	Annually	0.00%
CKHUY	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
LTOUF	Ex Dividend Junior	2023-08-01	Annually	0.00%
AILLO	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
YZCAY	Ex Dividend Junior	2023-07-03	Annually	0.00%
HEGIY	Ex Dividend Knight	2023-09-15	Semi-Annually	0.00%
SPKKY	Ex Dividend Knight	2023-09-14	Annually	0.00%
CYFL	Ex Dividend Knight	2023-09-05	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.372	1.500	2.55	3.83	[0 - 0.5]
returnOnAssetsTTM	0.114	1.200	6.19	7.43	[0 - 0.3]
returnOnEquityTTM	0.135	1.500	9.61	10.00	[0.1 - 1]
payoutRatioTTM	0.277	-1.000	7.23	-7.23	[0 - 1]
currentRatioTTM	5.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.20	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.67	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00820	-1.500	9.86	-10.00	[0 - 0.6]
interestCoverageTTM	19.09	1.000	4.04	4.04	[3 - 30]
operatingCashFlowPerShareTTM	541.64	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	442.41	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00941	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.859	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.394	1.000	4.12	4.12	[0.1 - 0.6]
cashFlowToDebtRatioTTM	13.28	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.307	0.800	-1.286	-1.029	[0.5 - 2]
Total Score				12.06

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	2.75	1.000	9.82	0	[1 - 100]
returnOnEquityTTM	0.135	2.50	9.75	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	442.41	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00551	1.500	9.86	0	[0 - 0.4]
operatingCashFlowPerShareTTM	541.64	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.277	1.500	7.23	-7.23	[0 - 1]
pegRatioTTM	0.00219	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.355	1.000	3.63	0	[0.1 - 0.5]
Total Score				5.85

Shionogi & Co., Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.